EMESIS DUE TO CANCER-CHEMOTHERAPY - RESULTS OF A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL OF VARYING DOSES OF METOCLOPRAMIDE IN THE MANAGEMENT OF CIS-PLATINUM-INDUCED VOMITING

被引：16

作者：

ALLAN, SG ^{[1
]}

CORNBLEET, MA ^{[1
]}

LOCKHART, SP ^{[1
]}

WARRINGTON, PS ^{[1
]}

LEONARD, RCF ^{[1
]}

SMYTH, JF ^{[1
]}

机构：

[1] WESTERN GEN HOSP, DEPT CLIN ONCOL, MED ONCOL UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1984年 / 20卷 / 12期

关键词：

D O I：

10.1016/0277-5379(84)90140-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A randomized, double-blind prospective trial was conducted to determine the relative antiemetic efficacy of 3 dose levels of metoclopramide in cancer patients receiving combination chemotherapy including cis-platinum. With consecutive courses of chemotherapy, 60 patients received doses of 3,5 or 10 mg/kg metoclopramide (50, 54 or 55 courses, respectively) in a randomly assigned sequence. Major control of emesis (.ltoreq. 2 vomits) was achieved in 38% of 159 patient treatments. There were no significant differences in antiemetic efficacy or the incidence of side-effects between the 3 doses used. While metoclopramide is an effective antiemetic for patients receiving cis-platinum therapy, no advantage apparently accrues to the use of doses in excess of 3 mg/kg (total dose).

引用

页码：1481 / 1484

页数：4

共 13 条

[1]

AAPRO MS, 1981, CANCER CHEMOTH PHARM, V7, P11

[2]

BUI NB, 1982, CANCER TREAT REP, V66, P2107

[3] ANTI-EMETIC EFFICACY OF HIGH-DOSE METOCLOPRAMIDE - RANDOMIZED TRIALS WITH PLACEBO AND PROCHLORPERAZINE IN PATIENTS WITH CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING [J].